Business
IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development
About this update from In8bio, Inc.
[{"type":"text","content":"NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the appointment of Trishna Goswami, M.D. as Chief Medical Officer. “Trishna’s experience and skills as a leader in immuno-oncology drug development aligns perfectly with our goals to advance multiple gamma-delta T cell therapeutic candidates through clinical development and approval,” said William Ho, Chief Executive Officer of IN8bio. “Her successful track record at leading companies such as Gilead, Immunomedics, Stemline Therapeutics and AstraZeneca/MedImmune makes her a highly valuable addition to our Company. I, along with my colleagues and the Board of Directors, welcome Trishna to IN8bio and look forward to her contributions.” Dr. Goswami has extensive experience managing the clinical development and regulatory approval of oncology product candidates, including those for both solid and hematologic tumors. She is a triple board-certified hematologist oncologist who brings more than a decade of industry experience in drug development across small molecule and biological assets including antibody-drug conjugates, monoclonal antibodies and immune therapies. “Gamma-delta T cells have increased in prominence as a cellular therapy that has the potential to revolutionize cancer therapy,” said Dr. Goswami. “This T cell subtype has both innate and adaptive characteristics and can be engineered and employed as cancer therapeutics that bridge the benefits of both arms of the immune system. IN8bio’s DeltEx platform leverages genetic engineering and advanced manufacturing to generate gamma-delta T cells with attributes such as chemotherapy resistance, which have the potential to improve treatments for cancers. I look forward to working with the team to advance their current clinical candidates and move future pipeline projects for new indications into clinical development. I look forward to working with the team to advance their current clinical candidates and move future pipeline projects for new indications into clinical development.” Dr Goswami most recently served as Vice President, Clinical Development at Gilead Sciences, Inc. (via its $21 billion acquisition of Immunomedics in 2020) where...